Albert Bourla, Pfizer CEO (John Thys, Pool via AP Images)
May 3, 2022 02:12 PM EDTUpdated May 9, 09:35 PM
Pharma
Marketing

Pfiz­er’s Covid sto­ry — and rev­enue spree — con­tin­ue with $54B vac­cine and pill in spot­light again

Beth Snyder Bulik

Senior Editor

Covid, Covid and more Covid news and ques­tion­ing dom­i­nat­ed Pfiz­er’s fi­nan­cial call with in­vestors on Tues­day — and of course, its top line rev­enue.

Pfiz­er re­port­ed …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
ENDPOINTS CAREERS

Director of IT, Security

Viridian Therapeutics

Waltham, MA, USA

TRENDING NOW

Bio­phar­ma be­gins to con­tem­plate an RFK Jr.-in­flu­enced FDA if Trump wins

Pfiz­er shares new de­tails on obe­si­ty pipeline, hints at ‘oth­er op­por­tu­ni­ties’

GSK buys au­toim­mune T cell en­gager for $300M up­front from Chim­a­gen

No­var­tis takes $800M Mor­phoSys write­down mere months af­ter clos­ing ac­qui­si­tion

No­var­tis high­lights over­all M&A track record fol­low­ing Mor­phoSys im­pair­ment

Fol­low­ing March in­spec­tion, No­vo Nordisk's semaglu­tide man­u­fac­tur­ing fa­cil­i­ty cit­ed by FDA

A service from the Financial Times